A new approach to treating depression; a non-profit’s role in approval for psilocybin | C L Raison

MD Charles L. Raison | Director of Clinical and Translational Research, Usona Institute
https://insight-conference.eu/speaker/charles-l-raison/

A new approach to treating depression; a non-profit’s role in advancing the science and regulatory path to approval for psilocybin

Depression is the leading cause of disability worldwide, affecting more than 300 million people, according to the World Health Organization. It can reduce life expectancies by an average of 10 years and may lead to suicide from which nearly 800,000 people die each year. There is an urgent need to identify and test novel treatments that may benefit people suffering from depression.
A series of academic studies have shown that a single high dose of the psilocybin produces a rapid and durable reduction in depression — even in patients who have failed currently approved antidepressants. Like other psychedelics, the pharmacological profile of psilocybin is novel and the nature of its clinical activity represents a new paradigm in the treatment of mental illness.

Usona Institute, a 501(c)3 nonprofit Medical Research Organization based in Madison, Wisconsin, USA, was founded in 2014 for the purpose of moving the highly encouraging early-phase psilocybin studies at UCLA, Johns Hopkins, and New York University, and others through the necessary phases of FDA-regulated clinical trials with the aim of an FDA new drug approval. Usona’s first psilocybin clinical trial will begin in late 2019, and will examine the safety and efficacy of psilocybin for the treatment of major depressive disorder (MDD).
In this presentation, Dr. Charles Raison will discuss the unmet medical need in depression treatment, the results of promising academic studies to date, and Usona’s unique role in sponsoring FDA-regulated clinical trials as a nonprofit medical research entity following an Open Science approach to research and drug development.

--------------------
We are a non-profit organisation - but you can support our work with a donation! With your tax-deductible donation we can achieve our goals and visions. Every euro or dollar you donate will fund a project or researcher who is committed to safe and legal therapies, harm reduction and the development of the European health system. Please indicate "Raison Video" as the intended purpose.
Link: https://mind-foundation.org/donate
-----------------------

Charles Raison, MD, is the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families and Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison in Madison, WI. Dr. Raison also serves as Director of Clinical and Translational Research for Usona Institute and as Director of Research on Spiritual Health for Emory Healthcare in Atlanta, GA. In addition, Dr. Raison has served as mental health expert for CNN.com for many years. Dr. Raison is internationally recognized for his studies examining novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training. More recently, Dr. Raison has taken a leadership role in the development of psychedelic medicines as potential treatments for major depression. The recipient of several teaching awards, Dr. Raison has received research funding from the National Institute of Mental Health, National Center for Complementary and Alternative Medicine, and the Centers for Disease Control and Prevention. Dr. Raison received the Raymond Pearl Memorial Award from the Human Biology Association “in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness.” With Vladimir Maletic he is author of “The New Mind-Body Science of Depression” published by W.W. Norton in 2017. Dr. Raison serves on the Scientific Advisory Board for the American Foundation for Suicide Prevention.

Видео A new approach to treating depression; a non-profit’s role in approval for psilocybin | C L Raison канала MIND Foundation